Why Axsome Therapeutics Inc (AXSM) Stock Is Rising
As of 2026-11-06, Axsome Therapeutics Inc (AXSM) has a next-year EPS growth estimate of 234.85%. Featured in our EPS revision report on 2026-05-04.
Why AXSM Stock Is Rising
- +EPS Estimate Upgraded: Analysts raised Axsome Therapeutics Inc's next-year EPS growth estimate from 232.47% to 233.44% on 2026-11-02.
- →Estimate Trending Higher: Since detection, the estimate has moved up a net +1.41 pp to 234.85% across 1 upward revision.
- ·Current-Year Growth: Projected at 28.74%, supporting the forward estimate revision.
News Context
AXSM stock has been rising primarily because analysts raised the next-year EPS growth estimate to 233.44% from 232.47%, with the current estimate at
Generated 2026-11-06 · news as of 2026-11-06
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 234.85%
- EPS growth this year
- 28.74%
- EPS next quarter (est)
- -$0.08
- Last price
- $129.80
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-11-06 | 234.85% | 28.74% | -$0.08 | $129.80 |
| 2026-11-05 | 234.85% | 28.74% | -$0.08 | $129.80 |
| 2026-11-04 | 234.87% | 28.74% | -$0.08 | $137.00 |
| 2026-11-03 | 234.87% | 28.74% | -$0.08 | $139.61 |
| 2026-11-02 | 233.44% | 25.04% | -$0.05 | $136.01 |
| 2026-10-31 | 232.47% | 20.14% | -$0.63 | $144.43 |
| 2026-10-30 | 232.47% | 20.14% | -$0.63 | $144.43 |
| 2026-10-29 | 232.47% | 20.14% | -$0.63 | $143.45 |
| 2026-10-28 | 233.08% | 20.27% | -$0.63 | $143.51 |
| 2026-10-27 | 233.08% | 20.27% | -$0.63 | $142.20 |
| 2026-10-26 | 233.08% | 20.27% | -$0.63 | $144.06 |
| 2026-10-23 | 236.16% | 21.12% | -$0.62 | $145.04 |
| 2026-10-22 | 236.16% | 21.12% | -$0.62 | $156.07 |
| 2026-10-21 | 236.84% | 21.41% | -$0.61 | $156.31 |
| 2026-10-20 | 237.01% | 21.51% | -$0.60 | $159.58 |
| 2026-10-19 | 237.01% | 21.51% | -$0.60 | $155.81 |
| 2026-10-16 | 237.01% | 21.51% | -$0.60 | $157.14 |
| 2026-10-15 | 237.01% | 21.51% | -$0.60 | $161.79 |
| 2026-10-14 | 248.80% | 23.65% | -$0.58 | $162.22 |
| 2026-10-13 | 253.42% | 24.45% | -$0.56 | $156.32 |
| 2026-10-12 | 257.16% | 25.19% | -$0.55 | $166.00 |
| 2026-10-11 | 263.44% | 25.55% | -$0.55 | $168.35 |
| 2026-10-10 | 263.44% | 25.55% | -$0.55 | $168.35 |
| 2026-10-09 | 263.44% | 25.55% | -$0.55 | $168.35 |
| 2026-10-08 | 263.42% | 25.54% | -$0.54 | $170.08 |
| 2026-10-07 | 267.06% | 26.61% | -$0.52 | $172.97 |
| 2026-10-06 | 267.06% | 26.61% | -$0.52 | $174.34 |
| 2026-10-05 | 267.06% | 26.61% | -$0.51 | $177.08 |
| 2026-10-04 | 267.06% | 26.61% | -$0.51 | $179.25 |
| 2026-10-03 | 267.06% | 26.61% | -$0.51 | $179.25 |
Reports Featuring AXSM
Recent News
- AXSM Stock Has Slumped Nearly 20% Over The Past Month, But BofA Sees Selloff As OverdoneStocktwits
- Axsome Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswire
- AXSM Stock Hits Fresh 52-Week Lows As Launch Concerns Of Auvelity In Alzheimer's Care Outweigh Q3 BeatStocktwits
- AXSM Stock Hits Fresh 52-Week Lows As Launch Concerns Of Auvelity In Alzheimer's Care Outweigh Q3 BeatStocktwits
- Axsome Beats Handily As Auvelity Growth Accelerates, But A Battered Stock Shows Investors Still Doubt The RampEarnings Whispers
- Axsome Beats Handily As Auvelity Growth Accelerates, But A Battered Stock Shows Investors Still Doubt The RampEarnings Whispers
- Axsome Therapeutics Shares Rise 2.13% as Q3 Revenue Jumps 52% and Loss NarrowsInvestorsHub
- Axsome Therapeutics Shares Rise 2.13% as Q3 Revenue Jumps 52% and Loss NarrowsInvestorsHub
- Axsome: Q3 Earnings SnapshotAssociated Press
- Axsome: Q3 Earnings SnapshotAssociated Press
Screen Performance
Aggregate stats across all 2130 tickers our top-EPS-revision screen has flagged over the past 219 days.
- Median return since detection
- -3.9%
- % of tickers in the green
- 41%
- Median return on winners
- +23.3%
- Large revisions captured
- 2083
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Also Tracked by Our Screen
Frequently Asked Questions
Why did Axsome Therapeutics Inc (AXSM) stock go up recently?▾
Axsome Therapeutics Inc (AXSM) stock has risen following an analyst upgrade of its next-year EPS growth estimate from 232.47% to 233.44% on 2026-11-02. Since detection, the estimate has moved up a net +1.41 pp to 234.85%. EPS estimate upgrades are among the strongest leading indicators of stock outperformance.
What is Axsome Therapeutics Inc's next-year EPS growth estimate?▾
As of 2026-11-06, Axsome Therapeutics Inc (AXSM) has a next-year EPS growth estimate of 234.85%, based on analyst consensus.
When was the latest EPS estimate revision for AXSM?▾
The most recent revision occurred on 2026-11-05, when analysts adjusted the next-year EPS growth estimate from 234.87% to 234.85%.
What sector and industry does Axsome Therapeutics Inc belong to?▾
Axsome Therapeutics Inc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. AXSM appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Axsome Therapeutics Inc (AXSM) appears here because it was detected by our daily top-EPS-revision-performer screen.